Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
View Patent ↗The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.
1. A compound having the structure:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising an effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 , further comprising a second therapeutic agent selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.
4. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the compound according to claim 1 .
5. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the composition according to claim 2 .
6. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the composition according to claim 3 .
7. A compound having structure:
8. A pharmaceutical composition comprising an effective amount of the compound of claim 7 and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 8 , further comprising a second therapeutic agent selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.
10. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the compound according to claim 7 .
11. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the composition according to claim 8 .
12. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the composition according to claim 9 .